FINWIRES · TerminalLIVE
FINWIRES

$GSK

20 stories mentioning GSK

Every FINWIRES story that references GSK, newest first.

Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.

$BKD$GSK$LLY$NUVL$PTCT
Wire

Nuvalent Acquisition Fairly Valued, Competing Bid Seen as Unlikely, Wedbush Says

Nuvalent (NUVL) is fairly valued following GSK's (GSK) agreed acquisition of the company, with limited likelihood of a competing bid emerging, Wedbush Securities said in a Tuesday note.The brokerage said most logical strategic acquirers, including Pfizer (PFE), Roche and Bristol Myers Squibb (BMY), already have meaningful exposure to ALK- and ROS1-positive non-small cell lung cancer markets, making it difficult to justify a higher offer while achieving attractive returns.Wedbush said the deal validates the value of differentiated precision oncology assets with advantages in efficacy, tolerability, resistance mutation coverage and CNS penetration.The investment firm downgraded Nuvalent to neutral from outperform and lowered its price target to $124 from $125, matching the agreed tender offer price from GSK.Shares of Nuvalent rose more than 39% in Tuesday afternoon trading.Price: $123.12, Change: $+34.63, Percent Change: +39.13%

$GSK$NUVL
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.

$GSK$LLY$NRSN$NUVL
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.

$GSK$NUVL
Wire

Top Midday Stories: GSK to Acquire Nuvalent for $10.6 Billion in Cash; Apple Introduces Siri AI, But EU Launch to be Delayed

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were down in late-morning trading Tuesday, as a recent surge in chip stocks lost momentum.In company news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. The transaction includes a tender offer of $124 per share for all outstanding common stock, as GSK looks to expand its pipeline of lung cancer therapies, the company said. GSK shares were up 0.7% around midday, while those of Nuvalent were up 38.9%.Apple (AAPL) on Monday unveiled major software updates at its Worldwide Developers Conference, including Siri AI and the next generation of Apple Intelligence. Siri AI is deeply integrated across iPhone, iPad, Mac, Apple Watch and Vision Pro, the company said. The tech giant also introduced new parental controls and redesigned Screen Time, allowing parents to set age-appropriate protections, daily app time limits and communication safety features. Apple users in the European Union will not have Siri AI access on iOS 27 and iPadOS 27 when it launches due to requirements under the Digital Markets Act, the company said. Apple remains unable to reach an agreement with EU regulators on a framework that would let Siri AI launch on iPhone and iPad while adhering to privacy and security standards, it said. Apple shares were down 3.3%.Broadcom (AVGO) said Tuesday it is launching the AI XPV Platform alongside Apollo Global Management (APO) and Blackstone's (BX) Credit & Insurance Business to facilitate over 20 gigawatts in compute capacity for leading AI labs, including Anthropic and OpenAI, through 2028. The platform, which will use Broadcom's XPUs and networking solutions, launches Tuesday with an initial $35 billion tranche led by Apollo in partnership with Blackstone. Broadcom shares were down 4.0%, while Apollo and Blackstone shares were up 1.7% and 2.8%, respectively.CoreWeave (CRWV) will hold calls Tuesday with high-yield investors in Europe about potential dollar and euro bond sales, Bloomberg reported, citing a person familiar with the matter. The AI infrastructure provider has appointed JPMorgan Chase (JPM) to arrange the calls, the report said, citing the person. CoreWeave shares were down 4.7%.JPMorgan Chase plans to launch AI agents later this year that are capable of working autonomously for far longer than current versions, CNBC reported Tuesday, citing an interview with Chief Analytics Officer Derek Waldron. JPMorgan shares were down 0.6%.Price: $51.01, Change: $+0.37, Percent Change: +0.73%

$AAPL$APO$AVGO$BX$CRWV$GSK$JPM
Asia Markets

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, lifting 0.82% to 1,874.41 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which rose 7% and 4.5% respectively. They were followed by accommodations booking company trivago (TRVG) and telecommunications company Nokia (NOK), which increased 4.4% and 1.7% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Cellectis (CLLS), which fell 2.9% and 2.3% respectively. They were followed by pharmaceutical company Sanofi (SNY) and biopharmaceutical company Grifols (GRFS), which were down 2% each.The gainers from the UK were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which advanced 4.5% and 3.3% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Amarin (AMRN), which were up 1.7% and 1.6% respectively.The decliners from the UK and Ireland were led by biotech company Autolus Therapeutics (AUTL) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 4.2% and 2.4% respectively. They were followed by utilities company National Grid (NGG) and pharmaceutical company GSK (GSK), which lost 2% and 1.2% respectively.

$AMRN$AUTL$BDRX$BP$CLLS$EVAX$GRFS$GSK$MREO$NCNA$NGG$NOK$NVO$SNY$SQNS$TRVG
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Medtronic (MDT) said Wednesday it is planning to acquire medical technology firm SPR Therapeutics for an upfront cash payment of about $650 million. Medtronic shares were down 1%.GSK (GSK) said Wednesday it has started negotiations with the pan-Canadian Pharmaceutical Alliance for the use of Blenrep to treat adults with relapsed or refractory multiple myeloma, a type of blood cancer. GSK shares were fractionally higher.Immunovant (IMVT) shares surged 33% after it said Wednesday its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.

$GSK$IMVT$MDT
Wire

GSK, Pan-Canadian Pharmaceutical Alliance Start Talks for Blenrep to Treat Blood Cancer

GSK (GSK) said Wednesday it has started negotiations with the pan-Canadian Pharmaceutical Alliance for the use of Blenrep to treat adults with relapsed or refractory multiple myeloma, a type of blood cancer.The talks cover the use of Blenrep plus bortezomib and dexamethasone, or combined with pomalidomide and dexamethasone, the company said.Price: $50.97, Change: $-0.08, Percent Change: -0.16%

$GSK
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading

European equities traded in the US as American depositary receipts were down significantly late Tuesday morning, dropping 1.05% to 1,814.06 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and 3D printer company Materialise (MTLS), which advanced 7.5% and 3.1% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and internet advertising firm Criteo (CRTO), which were up 1.5% and 1% respectively.The decliners from continental Europe were led by accommodations booking site trivago (TRVG) and telecommunications company Nokia (NOK), which fell 5.2% and 4.3% respectively. They were followed by internet browser company Opera (OPRA) and semiconductor company Sequans Communications (SQNS), which dropped 1.9% and 1.8% respectively.The gainers from the UK were led by cruise line operator Carnival (CUK) and tobacco company British American Tobacco (BTI), which climbed 6.6% and 2.4% respectively. They were followed by pharmaceutical company GSK (GSK) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 2% and 1.1% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and telecommunications operator Vodafone Group (VOD), which fell 22% and 8.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and lender Lloyds Banking Group (LYG), which lost 5.2% and 3.7% respectively.

$AKTX$BTI$CLLS$CRTO$CUK$DBVT$GSK$LYG$MREO$MTLS$NOK$OPRA$SLN$SQNS$TRVG$VOD
Wire

Halozyme, GSK Enter Collaboration, Licensing Agreement

Halozyme Therapeutics (HALO) said Thursday it has entered into a global collaboration and license agreement with GSK (GSK).The company said GSK has licensed its Enhanze drug delivery technology for subcutaneous administration of oncology targets, including antibody drug conjugates, as well as an option for additional future drug targets.GSK will make an upfront payment and potential future milestone payments to Halozyme, in addition to royalties, the firm said.Price: $64.94, Change: $-1.41, Percent Change: -2.13%

$GSK$HALO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Start Week Lower

European equities traded in the US as American depositary receipts kicked off the week lower late Monday morning, falling 0.70% to 1,803.50 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company argenx (ARGX), which climbed 8.1% and 1.9% respectively. They were followed by petroleum refiner Equinor (EQNR) and biopharmaceutical company Grifols (GRFS), which advanced 1.8% and 1.5% respectively.The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 5.5% and 4.2% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which lost 3.3% and 1% respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which rose 9.2% and 2.8% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which were up 2.3% and 2.2% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and cruise line operator Carnival (CUK), which fell 2.2% and 1.6% respectively. They were followed by pharmaceutical company GSK (GSK) and biotech firm Trinity Biotech (TRIB), which were down 1.2% and 0.4% respectively.

$AKTX$AMRN$ARGX$AUTL$BBVA$BDRX$CLLS$CUK$EDAP$EQNR$GRFS$GSK$NCNA$SNY$SQNS$TRIB
Wire

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
Asia Markets

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were lower late Wednesday morning, declining 0.45% to 1,779.46 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications firm Nokia (NOK) and medical device maker EDAP (EDAP), which rose 6.1% and 3.8% respectively. They were followed by petroleum refiner Equinor (EQNR) and Banco Santander (SAN), which were up 2.7% and 1% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and healthcare tech firm Royal Philips (PHG), which fell 6.1% and 5.6% respectively. They were followed by internet browser company Opera (OPRA) and semiconductor company Sequans Communications (SQNS), which lost 3.2% and 3.1% respectively.The gainers from the UK were led by communications company WPP (WPP) and software firm Endava (DAVA), which advanced 2.7% and 1.2% respectively. They were followed by oil and gas company Shell (SHEL) and educational publisher Pearson (PSO), which increased 1% and 0.7% respectively.The decliners from the UK and Ireland were led by Akari Therapeutics (AKTX) and pharmaceutical company GSK (GSK), which fell 8% and 7% respectively. They were followed by Silence Therapeutics (SLN) and Mereo BioPharma Group (MREO), which were down 5.8% and 5.5% respectively.

$AKTX$CLLS$DAVA$EDAP$EQNR$GSK$MREO$NOK$OPRA$PHG$PSO$SAN$SHEL$SLN$SQNS$WPP
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Policy Decision

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.02% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% higher in Wednesday's premarket activity, ahead of the Federal Open Market Committee's policy decision.US stock futures were mixed, with S&P 500 Index futures up 0.01%, Dow Jones Industrial Average futures retreating 0.03%, and Nasdaq futures gaining 0.3% before the start of regular trading.The US Federal Reserve's Federal Open Market Committee will make its latest policy announcement at 2 pm ET, followed by a press conference by Fed Chair Jerome Powell.Mortgage applications declined in the week ending April 24 after a large increase in the previous week, as mortgage rates rose slightly, according to the Mortgage Bankers Association Wednesday.US housing starts rose to an annual pace of 1.502 million in March, topping forecasts of 1.38 million and increasing from 1.356 million previously.In March, US building permits fell to an annual rate of 1.372 million, missing expectations of 1.39 million and declining from 1.538 million in the prior reading.Durable goods orders rose 0.8% in March, beating expectations for a 0.5% increase and marking a rebound from the previous 1.2% drop.Weekly petroleum stocks data are due to be released at 10:30 am ET, followed by the Atlanta Federal Reserve Survey of Business Uncertainty for April at 11 am ET.In premarket activity, bitcoin was up by 1.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.8% higher, Ether ETF (EETH) advanced 1.6%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.7%, and the iShares US Technology ETF (IYW) was 0.5% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 1.6%, while the iShares Semiconductor ETF (SOXX) rose by 1.8%.United Microelectronics (UMC) shares were up more than 8% in Wednesday's premarket activity after the company reported Q1 earnings and revenue.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.7%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.6% lower.UBS Group (UBS) shares were up more than 5% pre-bell after the company reported higher Q1 earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.3%, while the Vanguard Industrials Index Fund (VIS) was flat and the iShares US Industrials ETF (IYJ) was down 1.1%.AerCap Holdings (AER) stock was up more than 5% before the opening bell after the company reported higher Q1 revenue.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.4%, the Vanguard Health Care Index Fund (VHT) lost 0.3%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was flat.GSK (GSK) stock was down more than 4% premarket even after the company reported higher Q1 core earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.1%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) retreated by 0.1%. The iShares US Consumer Staples ETF (IYK) advanced 0.5%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.4%. The VanEck Retail ETF (RTH) gained 0.1%, while the State Street SPDR S&P Retail ETF (XRT) was 0.2% lower.Yum China (YUMC) shares were up more than 3% pre-bell after the company reported Q1 adjusted earnings and revenue.EnergyThe iShares US Energy ETF (IYE) was up 0.9%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.2%.Phillips 66 (PSX) stock was up more than 1% before the opening bell after the company reported it swung to Q1 adjusted earnings.CommoditiesFront-month US West Texas Intermediate crude oil rose by 3.3% to $103.22 per barrel on the New York Mercantile Exchange. Natural gas retreated by 1.3% to $2.66 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 3.4%, while the United States Natural Gas Fund (UNG) was 1.3% lower.Gold futures for May were down by 0.7% at $4,576.40 an ounce on the Comex. Silver futures retreated by 0.9% to $73.05 an ounce. SPDR Gold Shares (GLD) was 0.6% lower, and the iShares Silver Trust (SLV) fell by 0.6%.

Dow JonesNasdaq CompositeS&P 500$AER$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$GSK$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$PSX$QQQ$RTH$SLV$SOXX$SPY$UBS$UMC$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD$YUMC
Research

Research Alert: Gsk Q1 Beat As Specialty Medicines Remains Strong, Reiterates 2026 Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GSK delivered a Q1 2026 beat with sales growing 2% Y/Y (5% CER), led by Specialty Medicines (+10% or +14% CER), particularly oncology with strong Jemperli and Ojjaara uptake, while Vaccines grew 4% CER on record Shingrix sales. Core EPS grew 4% or 9% CER to GBP0.465, ahead of the consensus of GBP0.44, supported by a favorable product mix and cost control that lifted the core operating margin by 1.0%-pt or 1.8%-pts CER. We view the Q1 update positively given the beat and margin expansion, though we are mindful of currency headwinds. GSK reiterated its 2026 guidance for 3%-5% sales growth and 7%-9% core operating profit growth (CER), which is broadly aligned with that of several peers like Sanofi and Roche despite implying slower growth versus 2025. We expect revenue to be supported by key Specialty Medicines products, with GSK targeting the segment to contribute more than 50% of sales by 2031 (Q1 2026: 42%), while recent acquisitions provide a much-needed boost to growth and the drug pipeline, in our view.

$GSK
Wire

GSK's Efimosfermin Receives FDA, EMA Designations for MASH

GSK (GSK) said Monday its liver therapy efimosfermin received Breakthrough Therapy Designation from the US Food and Drug Administration and Priority Medicines designation from the European Medicines Agency for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH.The FDA designation is intended to expedite the development and review of medicines, while the EMA designation provides scientific and regulatory support.The designations were supported by phase 2 data in patients with moderate to advanced and cirrhotic fibrosis, which showed improvement in liver fibrosis and MASH resolution versus placebo. The company said the therapy demonstrated a generally well-tolerated safety profile.Phase 3 trials in MASH patients with cirrhotic fibrosis are expected to start this year, the company said.Price: $54.48, Change: $+0.04, Percent Change: +0.06%

$GSK
Wire

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics; Shares Surge

AnaptysBio (ANAB) said Monday that it has completed the spinoff of its biopharma operations business First Tracks Biotherapeutics.Under the terms of the spinoff, Anaptys shareholders received one share of First Tracks for every share of Anaptys owned as of the close of business on April 6. First Tracks Bio common stock were set to begin trading Monday on the Nasdaq Global Select Market under the ticker symbol "TRAX."The company said it will now exclusively manage its financial collaborations with GSK (GSK) and Vanda for cancer medicine Jemperli and generalized pustular psoriasis treatment imsidolimab, respectively.Shares of AnaptysBio were up close to 8% in recent trading on Monday.Price: $48.39, Change: $+3.39, Percent Change: +7.53%

$ANAB$GSK$TRAX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.42% to 1,823.55 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and internet browser company Opera (OPRA), which advanced 4.4% and 3.7%, respectively. They were followed by petroleum refiner Equinor (EQNR) and software firm SAP (SAP), which increased 3.6% and 3.1%, respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which dropped 3% and 1.6%, respectively. They were followed by biopharmaceutical companies DBV Technologies (DBVT) and argenx (ARGX), which fell 1.3% and 1.1%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and communications company WPP (WPP), which rose 4.3% and 2.8%, respectively. They were followed by educational publisher Pearson (PSO) and oil and gas company BP (BP), which were up 2.4% and 2.1%, respectively.The decliners from the UK and Ireland were led by cruise line operator Carnival (CUK) and biopharmaceutical company Bicycle Therapeutics (BCYC), which lost 4.6% and 2.8%, respectively. They were followed by biopharmaceutical company NuCana (NCNA) and pharmaceutical company GSK (GSK), which were down 1.7% and 0.9%, respectively.

$ARGX$BCYC$BP$CLLS$CUK$DBVT$EQNR$EVAX$GSK$NCNA$OPRA$PSO$SAP$SQNS$WPP
Sectors

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.

$GDRX$GSK$IMMP$JANX$NVO
Sectors

Sector Update: Health Care

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.

$GSK